Eli Lilly Gains Crucial FDA Advantage in Weight-Loss Drug Race

Eli Lilly has secured a pivotal edge in the competitive landscape for next-generation weight-loss medications. The U.S. Food and Drug Administration (FDA) has agreed to review the company's new drug candidate, Orforglipron, under an accelerated procedure. This process, expected to take just one to two months, dramatically shortens the typical 10- to 12-month review timeline. Concurrently, fresh regulatory filings reveal that institutional investors have been building substantial positions in the pharmaceutical giant.

The company leveraged a "Commissioner's National Priority Voucher" to fast-track the application for its daily oral tablet, Orforglipron. This strategic move is timely. Rival Novo Nordisk recently gained approval for an oral version of Wegovy and has submitted paperwork for its dual-agonist candidate, CagriSema.

The expedited review could allow Eli Lilly to launch its product significantly earlier than initially projected. With the obesity treatment market expanding rapidly, each month of a head start can translate to billions in revenue.

Major Funds Increase Holdings

Confidence from professional money managers is evident in the latest 13F filings, released on December 29. These documents show several institutions meaningfully raised their stakes following strong third-quarter earnings, where Eli Lilly reported adjusted earnings per share of $7.02, soundly beating the $6.42 consensus estimate.

Should investors sell immediately? Or is it worth buying Eli Lilly?

Notable activity includes:
* NovaPoint Capital boosted its holding by 55.9%.
* Apollon Wealth Management increased its position by 11.2%, accumulating 42,686 shares valued at over $32 million.
* Greenwood Capital expanded its investment by 25.5%, a stake now worth more than $10 million.
* Kempner Capital Management established a new position, investing nearly $2 million.

Pioneering a Trillion-Dollar Valuation

Eli Lilly recently made history by becoming the first pure-play pharmaceutical firm to achieve a market capitalization exceeding $1 trillion. This milestone is largely fueled by the blockbuster success of tirzepatide, marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. In the first nine months of 2025, combined sales for these two formulations surpassed $15.5 billion.

Market analysts identify the pharmaceutical sector as a primary engine for broader market gains. The consensus price target for Eli Lilly stands near $1,155, implying an upside of approximately 7% from current levels.

All eyes are now on the upcoming fourth-quarter results, scheduled for release on February 5, 2026. Wall Street anticipates earnings per share of $7.30. With the accelerated regulatory pathway for Orforglipron, Eli Lilly is strategically positioned to defend and grow its market share against Novo Nordisk throughout 2026.